LS-4

LS-4 is a small molecule drug in preclinical development, originally developed at the University of Illinois at Urbana–Champaign, targeting both beta amyloid A4 protein (APP) and microtubule-associated protein tau (TAU) as modulators. In preclinical Alzheimer's disease models, LS-4 reduces both amyloid plaques and phosphorylated tau aggregates as well as microglia activation, and demonstrates increased binding affinity for soluble and insoluble Aβ aggregates through a novel amphiphilic structure. It also has metal (Cu2+) chelating properties which facilitates imaging and biodistribution studies relevant for detecting amyloid pathology in Alzheimer’s disease[2].